Reactivos e instrumentos para inmunología, biología celular y biología molecular.
 
> β-Nicotinamide mononucleotide [1094-61-7]

β-Nicotinamide mononucleotide [1094-61-7]

Imprimir Imprimir
Por favor conéctese

Referencia HY-F0004-100mg

embalaje : 100mg

Marca : MedChemExpress

Solicitar más información

Contact local distributor :


Teléfono : +1 850 650 7790

β-nicotinamide mononucleotide (β-NM) is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD+ intermediate. The pharmacological activities of β-nicotinamide mononucleotide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity.

Para uso exclusivo en investigación. No vendemos a pacientes.

β-Nicotinamide mononucleotide Estructura química

β-Nicotinamide mononucleotide Estructura química

No. CAS : 1094-61-7

Tamaño Precio Stock Cantidad
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in Water
ready for reconstitution
 En stock
Solution
10 mM * 1 mL in Water En stock
Solid
5 mg En stock
10 mg En stock
50 mg En stock
100 mg En stock
200 mg   Obtener un presupuesto  
500 mg   Obtener un presupuesto  
or Consulta para venta a granel

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Based on 15 publication(s) in Google Scholar

Other Forms of β-Nicotinamide mononucleotide:

  • β-Nicotinamide mononucleotide-d4 Obtener un presupuesto
Descripciòn

β-nicotinamide mononucleotide (β-NM) is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD+ intermediate. The pharmacological activities of β-nicotinamide mononucleotide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity[1].

IC50 & Target

Human Endogenous Metabolite

 

In Vitro

β-nicotinamide mononucleotide has several beneficial pharmacological activities. Mostly mediated by its involvement in NAD+ biosynthesis, the pharmacological activities of NMN include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity[1].
The intracellular NAD+ levels are significantly decreased by knockdown or knockout of Nampt (Nampt KD or Nampt KO) or treatment with Nampt inhibitor FK866, whereas NAD+ levels are dramatically increased by supplement of NAD+ precursors NAM or NMN (0.5-1 mM). NAD+ precursor NMN treatment inhibited CD8+ T cells activation and function[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

β-Nicotinamide mononucleotide Related Antibodies

Solvente y solubilidad
In Vitro: 

H2O : 83.33 mg/mL (249.33 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.9920 mL 14.9602 mL 29.9204 mL
5 mM 0.5984 mL 2.9920 mL 5.9841 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Calculadora de molaridad

  • Calculadora de dilución

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 100 mg/mL (299.20 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Pureza y Documentación

Purity: 99.90%

SDS (394 KB)

COA (253 KB) HNMR (269 KB) CNMR (262 KB) RP-HPLC (205 KB) LCMS (93 KB)

Instrucciones de manejo (2659 KB)
Referencias

  • [1]. Poddar SK, et al. Nicotinamide Mononucleotide: Exploration of Diverse Therapeutic Applications of a Potential Molecule. Biomolecules. 2019;9(1):34. Published 2019 Jan 21.  [Content Brief]

    [2]. Lv H, et al. NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion [published online ahead of print, 2020 Nov 3]. Cell Metab. 2020;S1550-4131(20)30554-4.  [Content Brief]

    [3]. Li J, et al. p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activities. Proc Natl Acad Sci U S A. 2019;116(39):19626-19634.  [Content Brief]

    [4]. Yoshino J, et al Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011;14(4):528-536.  [Content Brief]

  • [1]. Poddar SK, et al. Nicotinamide Mononucleotide: Exploration of Diverse Therapeutic Applications of a Potential Molecule. Biomolecules. 2019;9(1):34. Published 2019 Jan 21.

    [2]. Lv H, et al. NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion [published online ahead of print, 2020 Nov 3]. Cell Metab. 2020;S1550-4131(20)30554-4.

    [3]. Li J, et al. p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activities. Proc Natl Acad Sci U S A. 2019;116(39):19626-19634.

    [4]. Yoshino J, et al Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011;14(4):528-536.

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O 1 mM 2.9920 mL 14.9602 mL 29.9204 mL 74.8010 mL
5 mM 0.5984 mL 2.9920 mL 5.9841 mL 14.9602 mL
10 mM 0.2992 mL 1.4960 mL 2.9920 mL 7.4801 mL
15 mM 0.1995 mL 0.9973 mL 1.9947 mL 4.9867 mL
20 mM 0.1496 mL 0.7480 mL 1.4960 mL 3.7401 mL
25 mM 0.1197 mL 0.5984 mL 1.1968 mL 2.9920 mL
30 mM 0.0997 mL 0.4987 mL 0.9973 mL 2.4934 mL
40 mM 0.0748 mL 0.3740 mL 0.7480 mL 1.8700 mL
50 mM 0.0598 mL 0.2992 mL 0.5984 mL 1.4960 mL
60 mM 0.0499 mL 0.2493 mL 0.4987 mL 1.2467 mL
80 mM 0.0374 mL 0.1870 mL 0.3740 mL 0.9350 mL
100 mM 0.0299 mL 0.1496 mL 0.2992 mL 0.7480 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

β-Nicotinamide mononucleotide Related Classifications

  • Reference Standards
  • Natural Product Standards
  • Ketones, Aldehydes, Acids
  • Neurological Disease Cancer
  • Cancer Targeted Therapy Cancer Immunotherapy Cancer Metabolism and Metastasis
  • Metabolic Enzyme/Protease
  • Endogenous Metabolite
Help & FAQs

  • Keywords:

    β-Nicotinamide mononucleotide1094-61-7β-NM NMNEndogenous MetabolitecardioprotectiondiabetesAlzheimer'sdiseaseobesitycancerNADintermediateInhibitorinhibitorinhibit

Usted podría estar interesado también en los siguientes productos:



Referencia
Descripción
Cond.
Precio Sin IVA
HY-13515-50mg
Sirtinol [410536-97-9]
 50mg